Evidence map›Paper›PMID 37818181›Full record

ArticleWomen's health reports (New Rochelle, N.Y.)2023

Long-Term Outcome of Graves' Disease: A Gender Perspective.

Jan Calissendorff, Per Karkov Cramon, Bengt Hallengren, Selwan Khamisi, Mikael Lantz, Tereza Planck, Gabriel Sjölin, Göran Wallin, Mats Holmberg

Abstract read
In one paragraph

Article in Women's health reports (New Rochelle, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Observational
  4. Review
  5. Psychiatric complications in Graves' disease.European thyroid journal · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jan CalissendorffDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Per Karkov CramonDepartment of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Bengt HallengrenDepartment of Endocrinology, Skåne University Hospital, Malmö, Sweden.
Selwan KhamisiDepartment of Endocrinology, Uppsala University Hospital, Uppsala, Sweden.
Mikael LantzDepartment of Endocrinology, Skåne University Hospital, Malmö, Sweden.
Tereza PlanckDepartment of Endocrinology, Skåne University Hospital, Malmö, Sweden.
Gabriel SjölinFaculty of Medicine and Health, Örebro University Hospital, Örebro, Sweden.
Göran WallinDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Mats HolmbergANOVA, Karolinska University Hospital, Stockholm, Sweden.ORCID https://orcid.org/0000-0003-2884-9981

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: In gender-skewed conditions such as Graves' disease (GD), the outcome naturally becomes dominated by the majority. This may lead to gender-biased misunderstandings regarding treatment outcomes. This especially holds true when complications, such as depression, are unevenly distributed. We have, therefore, studied the long-term outcome of GD from a gender perspective. Materials and Methods: A cohort of 1186 patients with GD was included in a follow-up 6-10 years after inclusion. Choice of treatment, the feeling of recovery, long-term treatment, comorbidity, and quality of life were investigated with questionnaires. All results were studied sex-divided. Results: We included 973 women and 213 men. There was no difference between men and women in the choice of treatment. At follow-up, women scored significantly worse in the general questionnaire 36-item Short-Form Health Status (SF-36) domain bodily pain and in the thyroid-specific Thyroid-Related Patient-Reported Outcome (ThyPRO) domains depression, impaired sex life, and cosmetic complaints, all Conclusion: After treatment for GD, women were more affected by depression, impaired sex life, cosmetic issues, and bodily pain despite successful cure of hyperthyroidism. The prevalence of hypothyroidism was also doubled in women. Whether these observed gender differences reflect a worse outcome of GD in women or a natural consequence of a higher prevalence of these symptoms and autoimmunity in the female population is difficult to disentangle. Nevertheless, several years after GD, women reveal more persistent symptoms.

Indexed as

Graves diseaselong-term follow-upquality of life

Identifiers

PMID37818181
PMCPMC10561747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.